KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Acadia Pharmaceuticals (ACAD) Other Non-Current Assets (2016 - 2025)

Acadia Pharmaceuticals (ACAD) has 16 years of Other Non-Current Assets data on record, last reported at $7.8 million in Q4 2025.

  • For Q4 2025, Other Non-Current Assets rose 2085.24% year-over-year to $7.8 million; the TTM value through Dec 2025 reached $7.8 million, up 2085.24%, while the annual FY2025 figure was $7.8 million, 2085.24% up from the prior year.
  • Other Non-Current Assets reached $7.8 million in Q4 2025 per ACAD's latest filing, up from $3.0 million in the prior quarter.
  • Across five years, Other Non-Current Assets topped out at $9.5 million in Q2 2025 and bottomed at $359000.0 in Q4 2024.
  • Average Other Non-Current Assets over 5 years is $5.9 million, with a median of $5.8 million recorded in 2021.
  • Peak YoY movement for Other Non-Current Assets: plummeted 93.78% in 2024, then surged 2085.24% in 2025.
  • A 5-year view of Other Non-Current Assets shows it stood at $5.8 million in 2021, then changed by 0.0% to $5.8 million in 2022, then changed by 0.0% to $5.8 million in 2023, then tumbled by 93.78% to $359000.0 in 2024, then soared by 2085.24% to $7.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Other Non-Current Assets were $7.8 million in Q4 2025, $3.0 million in Q3 2025, and $9.5 million in Q2 2025.